ORIGINAL PAPER
Anti-CRP autoantibodies in systemic lupus erythematosus
Online publication date: 2009-08-11
Reumatologia 2009;47(3):136-142
KEYWORDS
ABSTRACT
Systemic lupus erythromatosus is a chronic inflammatory disease with autoimmunological origin. The etiology is complicated and not fully understandable, but it seems to be related with disturbances of apoptotic products removal, stemming from inadequate C-reactive protein amounts. The cause of low CRP concentrations, incompatible with the inflammatory process, can be due to its binding to anti-CRP antibodies with the formation of immunological complexes. In addition, the occurrence of antibodies against the C-reactive protein can be correlated with higher probability of clinical symptoms appearance. The frequency of anti-CRP antibodies occurrence in a group of 45 patients suffering from systemic lupus erythematosus came to 6.67%. No correlation was found between anti-CRP antibodies and serum concentration of C-reactive protein. This result indicates, that low values of CRP in systemic lupus erythematosus are not related to their binding with antibodies. There was no correlation between anti-CRP and the activity of the disease, but higher disease activity (SLEDAI) was observed in patients with higher levels of anti-CRP antibodies. Serum concentration of circulating nucleosomes was significantly higher in patients with low serum CRP.
REFERENCES (23)
1.
Bijl M, Limburg PC, Kahlenberg CG. New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth J Med 2001; 59: 66-75. .
2.
Sjöwall C, Bengtsson T, Skogh T. CRP and anti-CRP autoantibodies in systemic lupus erythematosus. Curr Rheumatol Rev 2005; 1: 81-89. .
3.
Munoz LE, Gaipl US, Franz S, et al. TRU – a disease of clearance deficiency. Rheumatology (Oxford) 2005; 44: 1101-1107. .
4.
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197. .
5.
Kishore U, Ghai R, Greenhough TJ, et al. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett 2004; 95: 113-128. .
6.
Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42: 23-30. .
7.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 1271-1277. .
8.
Rosenau BJ, Schur PH. Antibodies to C-reactive protein. Ann Rheum Dis 2006; 65: 674-676. .
9.
Robey FA, Jones KD, Steinberg AD. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 1985; 161: 1344-1356. .
10.
Bell SA, Du Clos TW, Khursigara G, et al. Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J Autoimmun 1995; 8: 293-303. .
11.
Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules – C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1 prevelence in Systemic Lupus Erythematosus. Ann NY Acad Sci 2007; 1108: 227-239. .
12.
Sjöwall C, Bengtsson A, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6: 87-94. .
13.
Kovacs A, Green F, Hansson LO, et al. A noved common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005; 178: 193-198. .
14.
Szalai AJ, Wu J, Lange EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005; 83: 440-447. .
15.
Figueredo MA, Rodriguez A, Ruiz-Yagüe M, et al. Auto-antibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006; 33: 1980-1986. .
16.
Minatani M, Shinichi A, Tetsuo S. Autoantibodies against C-reactive protein (CRP) in sera of patients with systemic rheumatic diseases. Mod Rheumatol 2001; 11: 127-131. .
17.
Sjöwall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren’s syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002; 19: 155-160. .
18.
Jönsen A, Bengtsson AA, Gunnarsson I, et al. Association of polymorphic variants of FcgRIIIa and CRP genes with nephritis in SLE. Abstract, ACR San Diego, 2005. .
19.
Nakahara C, Kanemoto K, Saito N, et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol 2001; 55: 365-370. .
20.
Zuniga R, Markowitz GS, Arkachaisri T, et al. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune depositis and Fcg receptor type IIa alleles. Arthritis Rheum 2003; 48: 460-470. .
21.
Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000; 12: 369-373. .
22.
Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367-1381. .
23.
Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996; 23: 253-260.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
